Reality Check on Chronic Lymphocyctic Leukemia
Market access for chronic lymphocyctic leukemia (CLL) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: More than half of the covered lives under Medicare formularies are restricted
- Class Trends: The FDA approved Verastem, Inc.'s Copiktra (duvelisib) for the treatment of adults with relapsed or refractory CLL after at least two treatments
- Key Findings: There is good coverage for CLL drugs, although many plans do not have drug-specific policies for the older chemotherapy agents
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.